AI-Powered Automatic Hematology Analyzer with RET Advances Diagnostic Capabilities of Laboratories
Posted on 12 May 2023
Currently, hematology analyzers can measure various parameters, although most instruments can only provide simple information. When doctors are faced with a large amount of data but do not have enough time to analyze and process it, they can experience information confusion and overload. As the amount of information generated by hematology analyzers increases, clinicians can be affected by excessive workload, resulting in overlooking of critical information. Now, a cutting-edge hematology analyzer applies artificial intelligence (AI) analysis to generate truly interpretable information which helps decrease turn-around time, minimize technical misclassifications and reduce the workload of clinicians.
The new DH-615 hematology analyzer from Dymind Biotechnology Co., Ltd. (Shenzhen, China) based on fluorescent nucleic acid staining technology and the company’s proprietary AI Cube technology combines 6-DIFF with RET, greatly improving identification of abnormal cells and enhancing the ability to analyze hematological diseases such as leukemia, anemia, etc. In comparison to the traditional flag alarm functions, AI Cube technology provides more comprehensive information which is truly interpretable for the analysis of diseases, rather than simply providing conclusive data. Using Al technology, the DH-615 provides the graphics of the normal group and the corresponding diseases of different degrees for the reference of clinicians, which is more intuitive and clear. The DH-615 hematology analyzer perfectly combines AI analysis technology and DMS (Data Management System) for technical integration and higher compatibility.
As one of the most common laboratory tests for anemia diagnosis, blood routine examination has an important initial screening significance for further diagnosis of anemia. Some of the key indicators associated with anemia in blood routine are RBC counting, HGB concentration, MCV, and Reticulocytes (RET). The DH-615 is the first cutting-edge hematology analyzer with RET, which improves efficiency and accuracy for clinical detection in anemia and other diseases. Using nucleic acid fluorescence staining technology, DH-615 can summarize the four types of RET into three parameters according to the different nucleic acid content in different types of RET (different fluorescence intensity), which are HFR (High Fluorescent Ratio), MFR (Middle Fluorescent Ratio) and LFR (Low Fluorescent Ratio). The detection of reticulocytes enhances testing for bone marrow erythropoiesis and related diseases.
In addition, the DH-615 supports automated sampling of venous and capillary whole blood, which reduces the pressure of blood collection while increasing the detection velocity and reducing the risk of biological contamination. With the function of automated capillary blood sampling, it completely solves the pain points of the complicated operation process in the laboratory. The DH615 series adopts self-developed software to achieve full-process management, which provides accurate and fast test results for the outpatient and emergency laboratory without manual operation.
Related Links:
Dymind Biotechnology Co., Ltd.
